FDA Approves Cefepime-Zidebactam Injection - Quiz - MDSpire

FDA Approves Cefepime-Zidebactam Injection

Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.

  • By

  • Kathryn Wighton

  • June 3, 2026

  • 2 min

Share

Original Source(s)

FDA Approves Cefepime-Zidebactam Injection

  • by Kathryn Wighton

  • June 3, 2026

Related Content

Can Endotoxin-Targeted Care Improve Sepsis Outcomes?

Biomarker-guided patient selection may help identify patients with sepsis who could benefit from endotoxin-targeted therapy, although confirmatory evidence is still needed.

Does Sedative Choice Shape Later Cognition?

Researchers examined long-term cognitive outcomes among children who received ICU sedation for acute respiratory failure.

Can LAI-CAB Sustain Long-Term PrEP Use?

A national claims analysis found modest uptake and declining persistence over 2 years despite increasing use of injectable HIV pre-exposure prophylaxis.